The World Health Organization (WHO) has announced an upcoming meeting of its Emergency Committee to assess whether mpox continues to pose a global health crisis. This disease, which has shown a persistent spread, particularly in Africa, has been classified as a public health emergency of international concern.

Mpox, formerly known as monkeypox, is caused by the monkeypox virus, a member of the Orthopoxvirus genus. Since its identification, mpox has primarily affected regions in Central and West Africa, but recent outbreaks have raised alarms globally. The disease may lead to severe health complications, including skin lesions, fever and fatigue, which could be fatal in some cases, especially among immunocompromised individuals.

The spread of mpox has been significant, with thousands of cases reported in multiple countries over the past few years. Data from WHO indicates that the disease is not limited to its endemic regions but is also being transmitted in areas where it was previously uncommon. This global spread underscores the need for heightened surveillance, public awareness and effective health responses to manage the crisis

In terms of diagnosis, mpox could be identified through various biological markers and testing methods. Polymerase Chain Reaction (PCR) tests are the most reliable way to confirm infection, while serological tests help identify antibodies to the virus. Treatment primarily focuses on alleviating symptoms, as there is no specific antiviral therapy currently approved for mpox. Vaccination with the smallpox vaccine has shown efficacy in preventing the disease and is recommended for high-risk individuals.

In summary, mpox remains a critical public health issue that requires continued vigilance and proactive measures. With the WHO's assessment imminent, it is essential to understand the disease's implications, promote effective diagnostic and treatment strategies and prioritize prevention efforts to mitigate its spread globally.